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Abstract Extracellular-superoxide dismutase (EC-SOD) is
bound to the vascular endothelial cell surface with an affinity
for heparan sulfate proteoglycan. The binding of EC-SOD to the
human umbilical vein endothelial cell (HUVEC) and bovine
aortic endothelial cell surface proteoglycans was significantly
decreased by the incubation with S-nitroso-N-acetyl-DL-penicil-
lamine (SNAP) and ( þ )-N-[(E)-4-ethyl-2-[(Z)-hydroxyimino]-5-
nitro-3-hexene-1-yl]-3-pyridine carboxamide (NOR4), potent
nitric oxide (NO) donors. NO derived from lipopolysaccharide-
stimulated J774 A-1 cells also decreased the binding of EC-SOD
to HUVEC, and this decrease was blocked by NG-nitro-L-
arginine, a nitric oxide synthase inhibitor. SNAP and NOR4 also
decreased the binding of EC-SOD to immobilized heparin.
Furthermore, the decomposed derivatives of NO donors and
sodium nitrite decreased the binding of EC-SOD. These
observations suggest that excess NO produced in the in-
flammatory conditions decreases the binding of EC-SOD to
the vascular endothelial cell surface, which results in a loss of
the ability to protect the endothelial cell surface from oxidative
stress. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
Key words: Extracellular-superoxide dismutase; Nitric oxide;
Nitrite; Endothelial cell ; Heparan sulfate proteoglycan;
Oxidative stress
1. Introduction
Extracellular-superoxide dismutase (EC-SOD) is a secretory
glycoprotein [1,2] and is the principal enzymatic scavenger of
superoxide in the extracellular space. EC-SOD has an a⁄nity
for heparin-like substances [3,4] and is present in the circula-
tion in equilibrium between the plasma phase and the glycos-
aminoglycans on the endothelium [5]. In a previous study, we
showed that the plasma EC-SOD level was associated with
age [6,7], and was elevated in patients with renal diseases
[8], and reduced in patients with a history of myocardial in-
farction [9]. Recently, we showed that the plasma EC-SOD
level was elevated in patients with homocysteinuria [10] via
decreasing the binding of EC-SOD to the endothelial cell sur-
face by the treatment of homocysteine [11]. Therefore, phys-
iological and pathological changes of heparan sulfate proteo-
glycans of the endothelial cell surface modulate the variation
of the amount of EC-SOD binding to the endothelial cell
surface, which widely a¡ects the plasma EC-SOD levels and
the oxidative conditions of the vascular system.
Nitric oxide (NO) is produced by three distinct isoforms of
nitric oxide synthase (NOS) [12] and regulates physiological
and pathological events in cellular systems. The induction of
inducible NOS (iNOS) is involved in the in£ammatory process
evoked by endogenous signals such as infectious agents, lipo-
polysaccharide (LPS) and in£ammatory cytokines, in phago-
cytes and other cells [13^17]. Excessive amounts of NO are
associated with plasma leakage and microvascular injury [18]
as well as cytotoxic e¡ects against host cells in the in£amma-
tory focus. NO reacts extremely rapidly with superoxide to
produce peroxynitrite [19], a potent mediator of oxidant-in-
duced cellular injury, and is ¢nally degraded to nitrite and
nitrate.
NO has been reported to degrade heparin and heparan sul-
fate on endothelial cells [20]. So NO or its derivatives might
decrease the amount of EC-SOD bound on the endothelial
cell surface. In the present study, we investigated the e¡ects
of NO and its decomposed derivatives on the binding of
EC-SOD to heparin and the endothelial cell surface.
2. Materials and methods
2.1. Reagents
NO donors S-nitroso-N-acetyl-DL-penicillamine (SNAP) and ( þ )-
N-[(E)-4-ethyl-2-[(Z)-hydroxyimino]-5-nitro-3-hexene-1-yl]-3-pyridine
carboxamide (NOR4), peroxynitrite donor 3-(4-morpholinyl) sydno-
nimine hydrochloride (SIN-1), and NOS inhibitor NG-nitro-L-arginine
(L-NNA) were purchased from Dojindo Laboratories (Kumamoto,
Japan). Human recombinant EC-SOD (r-EC-SOD), prepared as de-
scribed previously [2], was kindly provided by Symbicom AB (Umeafi,
Sweden). Heparin^bovine serum albumin (BSA) complex and LPS
(from Escherichia coli serotype O55:B5) were purchased from Sigma
(St. Louis, MO, USA). Mouse anti-r-EC-SOD monoclonal antibody
was prepared as described previously [21]. Alkaline phosphatase-
coupled rabbit anti-mouse IgG antibody was purchased from Zymed
Laboratories Inc. (San Francisco, CA, USA). Dulbecco’s modi¢ed
Eagle’s medium (DMEM) was obtained from Nissui Pharmaceutical
Co. (Tokyo, Japan). Human umbilical vein endothelial cells
(HUVEC) and bovine aortic endothelial cells (BAEC) were purchased
from Dainippon Pharmaceutical Co. Ltd. (Osaka, Japan). J774 A-1
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murine macrophage cells (JCRB9108) were purchased from Health
Science Research Resources Bank (Osaka, Japan). Immunoplates
and TC insert Anopore membrane eight-well strips were purchased
from Nunc (Roskilde, Denmark). Collagen Type I-coated 96-well mi-
croplates were purchased from Asahi Techno Glass Co. Ltd. (Tokyo,
Japan).
2.2. Binding of EC-SOD to endothelial cells
Binding of r-EC-SOD to the endothelial cells was performed as
described previously [11]. HUVEC or BAEC were suspended in
DMEM containing 10% (v/v) fetal calf serum (FCS), 100 U/ml pen-
icillin and 100 Wg/ml streptomycin and cultured in Collagen Type I-
coated 96-well plates. When the cells were nearly con£uent, the media
were replaced with fresh FCS-free DMEM and cultured for 24 h.
After the replacement of the medium with the fresh one, various
concentrations of NO donors were added or J774 A-1 cell-plated
TC inserts (as described below) were set on the wells, and followed
by incubation in a CO2 incubator for 24 h. Decomposed NO donors
were prepared by incubation in phosphate-bu¡ered saline (PBS) for
48 h at room temperature before use. The endothelial cell layers were
rinsed with DMEM containing 0.5% FCS, and r-EC-SOD dissolved in
the same medium was added followed by incubation at 4‡C for 1 h.
At the end of the incubation period, the unbound r-EC-SOD was
collected and the cells were washed twice with PBS. The cells were
then incubated at 4‡C for 30 min with 10 mg/ml of heparin dissolved
in the same medium to remove the cell surface-bound r-EC-SOD,
which was then quanti¢ed by ELISA [22].
2.3. NO generation from macrophage cells
J774 A-1 murine macrophage cells were cultured in DMEM con-
taining 10% (v/v) heat-inactivated FCS, 100 U/ml penicillin and
100 Wg/ml streptomycin. The cells were collected by scraping, mixed
with or without 10 Wg/ml LPS and/or 1 mM L-NNA, and then plated
into TC inserts at densities of 5U104 or 1U105 cells/well. The TC
inserts were set on the 96-well plate in which HUVEC was cultured
con£uently as described above. Production of NO was assayed by
measuring the accumulation of nitrite in the conditioned media by
the Griess reaction [23].
2.4. Binding of EC-SOD to immobilized heparin
Binding of r-EC-SOD to immobilized heparin was performed as
described previously [11]. Brie£y, immunoplate wells were coated
with 100 Wl of 50 mM Tris^HCl, pH 7.4, containing 12.7 mM
EDTA and 0.4 Wg/ml heparin^BSA complex and left to stand over-
night at 4‡C. Each well was washed three times with PBS containing
0.05% (v/v) Tween 20 (PBS-Tween), blocked with PBS-Tween con-
taining 1% (w/v) BSA, and the plates were then left to stand overnight
at 4‡C.
A volume of 100 Wl of the various concentrations of NO donors or
the other reagents diluted in PBS was added to each well and the
plates were kept for 24 h in a CO2 incubator. The wells were then
rinsed once with DMEM containing 0.5% (v/v) FCS and incubated
for 3 h with r-EC-SOD diluted in the same medium. The wells were
washed three times with PBS-Tween, and bound r-EC-SOD was then
determined by the method mentioned above.
2.5. Statistical analysis
The data shown are the means þ S.D. of three or four separate
experiments. Statistical signi¢cance was estimated using the Student’s
t-test, and a value of P6 0.05 was considered to be statistically sig-
ni¢cant.
3. Results
3.1. E¡ects of NO on r-EC-SOD binding to the endothelial
cells
It is known that EC-SOD can bind to cultured anchorage-
dependent cell lines including endothelial cells [11,24]. We
assessed whether NO a¡ects the binding of EC-SOD to the
endothelial cells. As shown in Fig. 1A, the amount of r-EC-
SOD bound to the HUVEC surface was signi¢cantly de-
creased by pretreatment with SNAP or NOR4 in a concen-
tration-dependent manner. The binding of r-EC-SOD to HU-
VEC surface was reduced to 74.0% (P = 0.005) and 74.1%
(P = 0.019) with 200 WM SNAP or NOR4, respectively. The
decrease of the binding of r-EC-SOD by NO donors was also
observed in BAEC as well as HUVEC (Fig. 1B), which sug-
gests that this phenomenon commonly occurs in the vascular
wall in vivo.
3.2. E¡ects of NO released from macrophages on r-EC-SOD
binding to the endothelial cells
In in£ammatory conditions, LPS or cytokines have been
shown to stimulate the expression of iNOS and NO produc-
tion by several cells, especially by macrophages [13,14]. There-
fore we studied the change of r-EC-SOD binding to HUVEC
treated with macrophage-derived NO, using a TC insert cul-
ture system. As shown in Fig. 2A, the binding of r-EC-SOD
to HUVEC was signi¢cantly decreased by co-culture of J774
A-1 cells in the presence of 10 Wg/ml LPS. Addition of L-
NNA, an NOS inhibitor, to the above reaction mixture re-
versed the binding of r-EC-SOD to HUVEC, whereas L-NNA
alone did not a¡ect it (Fig. 2B). The amounts of NO released
from the J774 A-1 cells supported the above observations
(Fig. 2C and D). These results indicate that NO released by
LPS-stimulated J774 A-1 cells as well as NO donor decreases
r-EC-SOD binding to the endothelial cells.
Fig. 1. Inhibition of EC-SOD binding to the endothelial cells by NO donors. A: NO donor concentration-dependent inhibition of r-EC-SOD
binding to HUVEC. HUVEC was incubated with various concentrations of SNAP (¢lled columns) or NOR4 (hatched columns) for 24 h.
B: Inhibition of r-EC-SOD binding to the endothelial cells. HUVEC and BAEC were incubated without (open columns) or with 100 WM of
SNAP (¢lled columns) or NOR4 (hatched columns) for 24 h. The cells were followed by addition of r-EC-SOD as described in Section 2. The
amounts of bound r-EC-SOD were determined by ELISA. Data represent the means þ S.D. of four experiments. *P6 0.05 vs. control.
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3.3. E¡ects of NO on r-EC-SOD binding to immobilized
heparin
Because EC-SOD binds to the vascular endothelial cells via,
especially, heparin-like heparan sulfate proteoglycans on the
endothelial cell surface, we next assessed the e¡ects of NO on
the binding of EC-SOD to heparin. The amount of r-EC-SOD
binding to immobilized heparin was signi¢cantly decreased by
pretreatment with NO donors in a concentration- and time-
dependent manner (Fig. 3). The binding of r-EC-SOD was
signi¢cantly reduced to 66.6% of the control (P = 0.017) by
20 WM SNAP and to 73.6% (P = 0.012) by 10 WM NOR4
for 24 h. The decrease of the binding of r-EC-SOD to immo-
bilized heparin was observed after more than 3 h incubation
with 100 WM SNAP or NOR4.
3.4. E¡ects of decomposed derivatives of NO on r-EC-SOD
binding
We next studied whether the decomposed NO donors
Fig. 2. Inhibition of EC-SOD binding to HUVEC by macrophage-derived NO. A: Inhibition of r-EC-SOD binding to HUVEC by J774 A-1
cells stimulated with LPS. HUVEC were incubated for 24 h with 5U104 or 1U105 cells/well of J774 A-1 cells mixed without (open columns)
or with 10 Wg/ml LPS (¢lled columns). B: E¡ect of NOS inhibitor on the decrease of the binding of r-EC-SOD to HUVEC by LPS-stimulated
J774 A-1 cells. HUVEC and 5U104 cells/well of J774 A-1 cells mixed with or without 10 Wg/ml LPS and/or 1 mM L-NNA were incubated for
24 h. The conditioned media of the above experiments were collected and the nitrite concentrations were measured by the Griess reaction
(C and D). Data represent the means þ S.D. of three experiments. *P6 0.05, #P6 0.001 vs. control.
Fig. 3. Inhibition of EC-SOD binding to immobilized heparin by NO donors. A: NO donor concentration-dependent inhibition of r-EC-SOD
binding to immobilized heparin. Heparin^BSA-coated plates were incubated with various concentrations of SNAP (¢lled columns) or NOR4
(hatched columns) for 24 h and then the binding of r-EC-SOD was assayed. B: Time-dependent inhibition of r-EC-SOD binding to immobi-
lized heparin. Heparin^BSA-coated plates were incubated without (open columns) or with 100 WM SNAP (¢lled columns) or 100 WM NOR4
(hatched columns) for the indicated times and then the binding of r-EC-SOD was assayed. The amounts of bound r-EC-SOD were determined
as described in Section 2. Data represent the means þ S.D. of four experiments. *P6 0.05, #P6 0.001 vs. control.
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would decrease the binding of r-EC-SOD to the endothelial
cells and immobilized heparin. As shown in Fig. 4A, the bind-
ing of r-EC-SOD to HUVEC was also signi¢cantly inhibited
by decomposed NO donors as well as active NO donors. We
observed no signi¢cant di¡erences of the potentialities be-
tween active and decomposed NO donors. Moreover, the
binding was also reduced to 73.5% (P = 0.012) by sodium
nitrite, a stable product of NO in aqueous solution (Fig.
4B). Similar to the binding to HUVEC, decomposed NO do-
nors and sodium nitrite markedly inhibited the binding of r-
EC-SOD to immobilized heparin (Fig. 4C and D). In contrast,
peroxynitrite donor SIN-1 or nitrate did not decrease the
binding of EC-SOD (data not shown). NO donors and nitrite
did not a¡ect cellular protein contents at the concentration
used (data not shown). These results demonstrate that NO
derivatives, especially nitrite, also inhibited the r-EC-SOD
binding to heparin and the endothelial cells.
4. Discussion
EC-SOD binds to the endothelial cells by the interaction of
C-terminal basic amino acids with anionic charged residues in
heparan sulfate proteoglycan or other proteoglycans on the
endothelial cell surface [25]. In this study, we found that exog-
enous NO decreased r-EC-SOD binding to the endothelial cell
surface. The NO productions from 100 WM SNAP and NOR4
for 24 h were 52.5 þ 0.9 and 64.2 þ 3.2 WM, respectively under
the experimental conditions shown in Fig. 1, which are con-
sistent with plasma concentration of nitrite in in£ammatory
conditions [26,27]. It is known that large amounts of NO were
produced by several cells including macrophages, endothelial
cells and smooth muscle cells, stimulated by in£ammatory
cytokines or LPS [15,28^30]. We found that the co-culture
with LPS-stimulated J774 A-1 cells decreased the binding abil-
ity of HUVEC with r-EC-SOD, as shown in Fig. 2. The de-
crease of the binding of r-EC-SOD was accompanied with NO
release measured by the Griess reaction and was blocked by
NOS inhibitor. These results suggest that large amounts of
NO released from activated macrophages would cause the
decrease of EC-SOD binding to the endothelial cell surface,
followed by the decrease of capacity to scavenge superoxide in
the microenvironment of the vascular system, causing vascular
injury.
As shown in Fig. 4, decomposed NO donors as well as
active donors reduced r-EC-SOD bindings to HUVEC and
to immobilized heparin. One of the stable end products of
NO in aqueous solution is nitrite [31,32]. The question of
nitrite as a new potent oxidant has recently been raised. Ni-
trite levels of plasma and other tissue £uids were elevated in
several in£ammatory diseases including chronic glomerular
nephritis [26], cerebral systemic lupus erythematodes [33]
and infective gastroenteritis [34], but the mechanism causing
oxidative stress remains poorly understood. Recently, it has
been suggested that nitrite can be oxidized by myeloperoxi-
dase, an enzyme secreted from activated neutrophils, to form
nitrogen dioxide or a related species, which can contribute to
tyrosine nitration during in£ammatory processes [35,36].
Moreover, nitrous acid (HNO2) is known to cleave heparin
and heparan sulfate at N-sulfate or free amino glucosamine
residues by a deaminative mechanism [37^40]. The active spe-
cies, the nitrosonium cation (NO), may be formed directly
from NO or HNO2 in the presence of an appropriate electron
Fig. 4. Inhibition of EC-SOD binding by decomposed derivatives of NO. HUVEC (A and B) or heparin^BSA-coated plates (C and D) were in-
cubated without (open columns) or with 100 WM active (hatched columns) or decomposed (¢lled columns) SNAP or NOR4 (A and C), various
concentrations of sodium nitrite (B and D) for 24 h and then the binding of r-EC-SOD was assayed. Data represent the means þ S.D. of four
experiments. *P6 0.05, #P6 0.001 vs. control, N.S., no signi¢cant di¡erence.
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acceptor. Along with cleavage of the glycosidic bond, the
amino group and the sulfate group are known to be elimi-
nated, yielding an anhydromannose at the new reducing end
of each oligosaccharide [40]. Our observation that sodium
nitrite decreased r-EC-SOD binding to the endothelial cell
surface and immobilized heparin might be explained by these
mechanisms. In contrast, the results that peroxynitrite did not
decrease r-EC-SOD binding to heparin-like substances are
consistent with a previous report that peroxynitrite did not
degrade heparin and heparan sulfate [20]. Therefore, it is sug-
gested that the main material that decreases the EC-SOD
binding to heparin-like substances is NO or its decomposed
derivatives, including nitrite.
The blood vessel walls were found to contain large amounts
of EC-SOD, whereas the levels of other SOD isozymes were
relative low, and EC-SOD was shown to be distributed
throughout the wall with signi¢cant amounts in all layers
[41]. It is possible that EC-SOD in the vascular system di¡uses
into the extracellular space and suppresses the oxidative stress
by scavenging superoxide. We have reported that reduction of
heparin a⁄nity of EC-SOD contributes to endothelial dys-
function [42]. Elimination of EC-SOD from the endothelium
by NO derivatives may result in the elevation of oxidative
stress.
In conclusion, our study demonstrated that the binding of
EC-SOD to glycosaminoglycans was signi¢cantly decreased
by macrophage-derived NO, and NO donors and their decom-
posed derivatives, especially nitrite. These ¢ndings suggest
that excess NO decreases the protection of the vascular endo-
thelial cell surface from superoxide and results in the patho-
genesis of in£ammation and the other oxidative stress-derived
diseases.
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